3. Producción

Browse

Settings

Subject: search.filters.subject.Parkinson's disease

Search Results

Now showing 1 - 2 of 2
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Gut microbiota and Parkinson's disease
    (2021-12-01)
    It is possible for the non-motor symptoms (NMS) of Parkinson's disease (PD), which include constipation, sleep difficulties, and olfactory impairments, to appear up to 20 years before the motor symptoms of the disease. There is a growing body of research that suggests the pathology of Parkinson's disease may begin in the gastrointestinal tract and progress to the brain. Numerous studies provide credence to the idea that the microbiota in one's gut communicates with one's brain in Parkinson's disease (PD) via way of the immune system, a certain amino acid metabolism, and the neurological system. Through what has become known as the "gut microbiota-brain axis" (GMBA), the gut microbiota is thought to play an important part in the modulation of several neurochemical pathways.In the process of mediating the crosstalk between the gut microbiota and the physiology of the host, many of the metabolites produced by the gut microbiota, such as fatty acids, amino acids, and bile acids, carry signaling activities. In Parkinson's disease (PD), the quantity of amino acids and species-specific alterations of amino acids, such as glutamate and tryptophan, may interfere with the signaling transmission between nerve cells and disrupt the normal operation of the basal ganglia. Certain amino acids and the receptors that bind to them are being looked at as new possible targets for the treatment of PD. The of the current investigation was to compile and analyze all of the evidence that is currently available on the gut microbiota-derived amino acid metabolic changes that are related with PD.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Locally adapting digital health technologies to address the global challenge of Parkinson's disease
    (2025-08-29)
    Parkinson's disease is the fastest growing neurological disorder worldwide. As the global burden of the disease continues to grow, along with the environmental consequences of industrialization, it remains essential to diagnose, treat, and study Parkinson's disease among historically marginalized populations living in remote and relatively unindustrialized regions of the world. The diagnosis and monitoring of the motor manifestations of the disease depends on in-person examination of the speed, amplitude, and frequency of movement by trained providers. Digital health technologies allow synchronous, remote, video-based access to trained providers able to diagnose and monitor the progression of Parkinson's disease using clinical rating scales. Digital health technologies can be expensive, and their use requires sustainable access to trained providers, powerful computers and high-speed internet that are not widely available for historically marginalized populations, such as those living in remote Andean regions of Latin America. Local adaptation of health technologies could be promoted in partnership with historically marginalized communities to study their unique epidemiology while building local capacity to expand care and support community-driven education and research efforts.
      3